Gastrointestinal

Inflammatory bowel disease

[Article] Vítek L, Tiribelli C. “Bilirubin, Intestinal Integrity, the Microbiome, and Inflammation”. New Engl J Med. 2020;383:684–686. (IF: 91.245)

[Article] Lee Y, Sugihara K, Gillilland MG, Jon S, Kamada N, Moon JJ. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis”. Nat Mater. 2020;19:118–126. (IF: 48.841)

[Article] Lee Y, Kim H, Kang S, Lee J, Park J, Jon S. “Bilirubin Nanoparticles as a Nanomedicine for Anti-inflammation Therapy”. Angewandte Chemie Int Ed. 2016;55:7460–7463. (IF: 15.336)

Liver

Hepatic Steatosis

[Article] Hinds TD, Creeden JF, Gordon DM, Stec DF, Donald MC, Stec DE. “Bilirubin Nanoparticles Reduce Diet-Induced Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma β-Hydroxybutyrate”. Front Pharmacol. 2020;11:594574. (IF: 5.81)

Cardiovascular

Myocardial infarction

[Article] Ai W, Bae S, Ke Q, Su S, Li R, Chen Y, Yoo D, Lee E, Jon S, Kang PM. “Bilirubin Nanoparticles Protect Against Cardiac Ischemia/Reperfusion Injury in Mice”. J Am Heart Assoc. 2021;10:e021212. (IF: 5.501)

Respiratory

Asthma

[Article] Kim DE, Lee Y, Kim M, Lee S, Jon S, Lee S-H. “Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma”. Biomaterials. 2017;140:37–44. (IF: 12.479)

Pulmonary Fibrosis

[Article] Keum H, Kim D, Kim J, Kim TW, Whang C-H, Jung W, Jon S. “A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis”. Biomaterials. 2021;275:120986–120986. (IF: 12.479)

Transplantation

Ischemic Reperfusion Injury

[Article] Kim JY, Lee DY, Kang S, Miao W, Kim H, Lee Y, Jon S. “Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury”. Biomaterials. 2017;133:1–10. (IF: 12.479)

Transplantation

[Article] Kim MJ, Lee Y, Jon S, Lee DY. “PEGylated bilirubin nanoparticle as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation”. Biomaterials. 2017;133:242–252. (IF: 12.479)

Kidney Transplantation

[Article] Lee J, Kim EJ, Lee JG, Kim BS, Huh KH, Kim MS, Kim SI, Kim YS, Joo DJ. “Clinical impact of serum bilirubin levels on kidney transplant outcomes”. Sci Rep-uk. 2021;11:6889. (IF: 4.379)

GvHD

[Article] Pareek S, Flegle AS, Boagni D, Kim JY, Yoo D, Trujillo-Ocampo A, Lee S-E, Zhang M, Jon S, Im JS, “Post Transplantation Bilirubin Nanoparticles Ameliorate Murine Graft Versus Host Disease via a Reduction of Systemic and Local Inflammation”. Front Immunol. 2022;13:893659. (IF: 7.97)

[Article] PAreek S, Zhang M, Trujillo-Ocampo A, Kim J, Jon S, Im JS. “Bilirubin Nanoparticle as an anti-inflammatory therapy for graft versus host disease”. J Immunol. 2018;200 (1 Supplement) 55:22. (IF: 5.422)

Neuropathy

Multiple sclerosis

[Article] Kim TW, Kim Y, Jung W, Kim DE, Keum H, Son Y, Jon S. “Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells”. J Control Release. 2021;331:74–84. (IF: 9.776)

Skin

Psoriasis

[Article] Keum H, Kim TW, Kim Y, Seo C, Son Y, Kim J, Kim D, Jung W, Whang C-H, Jon S. “Bilirubin nanomedicine alleviates psoriatic skin inflammation by reducing oxidative stress and suppressing pathogenic signaling”. J Control Release. 2020;325:359–369. (IF: 9.776)

Drug Delivery System

Cancer drug

[Article] Lee S, Lee Y, Kim H, Lee DY, Jon S. “Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy”. Biomacromolecules. 2018;19:2270–2277. (IF: 6.988)

[Article] Lee Y, Lee S, Jon S. “Biotinylated Bilirubin Nanoparticles as a Tumor Microenvironment-Responsive Drug Delivery System for Targeted Cancer Therapy”. Adv Sci. 2018;5:1800017. (IF: 15.444)

[Article] Lee DY, Kim JY, Lee Y, Lee S, Miao W, Kim HS, Min J, Jon S. “Black Pigment Gallstone Inspired Platinum-Chelated Bilirubin Nanoparticles for Combined Photoacoustic Imaging and Photothermal Therapy of Cancers”. Angewandte Chemie Int Ed. 2017;56:13684–13688. (IF: 15.336)

[Article] Lee Y, Lee S, Lee DY, Yu B, Miao W, Jon S. “Multistimuli-Responsive Bilirubin Nanoparticles for Anticancer Therapy”. Angewandte Chemie Int Ed. 2016;55:10676–10680. (IF: 15.336)

Diagnosis

Contrast agent

[Article] Lee DY, Kang S, Lee Y, Kim JY, Yoo D, Jung W, Lee S, Jeong YY, Lee K, Jon S. “PEGylated Bilirubin-coated Iron Oxide Nanoparticles as a Biosensor for Magnetic Relaxation Switching-based ROS Detection in Whole Blood”. Theranostics. 2020;10:1997–2007. (IF: 11.556)